Stock listing

Cardiol Therapeutics Inc. Class A

Selected listing: CT9 · FWB · EUR · DE

Cardiol Therapeutics Inc. Class A (Frankfurt:CT9), Health Technology. Latest release Sep 23, 2026: Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment…

CT9:FWBEURDEUpdated October 2, 2026

Ticker: Frankfurt:CT9
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Frankfurt
Currency: EUR

About Cardiol Therapeutics Inc. Class A

The company focuses on developing innovative therapies for cardiovascular diseases. Cardiol Therapeutics aims to address unmet medical needs in this critical area of healthcare.

Latest news from Cardiol Therapeutics Inc. Class A

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy

September 23, 2026

Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

September 16, 2026

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

September 10, 2026

Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

August 5, 2026

All Cardiol Therapeutics Inc. Class A news →

Research Cardiol Therapeutics Inc. Class A

Cardiol Therapeutics Inc. Class A company profile

View the public company page for Cardiol Therapeutics Inc. Class A on 6ix.

Cardiol Therapeutics Inc. Class A news

Read company news and market updates connected to Cardiol Therapeutics Inc. Class A.

Cardiol Therapeutics Inc. Class A investor events

Find investor webinars, events, and replay context for Cardiol Therapeutics Inc. Class A.